姓名：李霄鹤
职称：副教授
学科方向：分子药理学，细胞生物学
招生方向：分子与细胞生物学，微生物与生化药学，生物工程与制药学
通讯地址：天津市津南区海河教育园同砚路38号南开大学药学院，300350
电话：022-85358566
电子邮件：lixiaohe908@nankai.edu.cn
【主要研究方向】
1. 肺间质病创新疾病靶点机制研究及药物研发
2. 器官纤维化（皮肤、心脏、肾脏纤维化）创新靶点机制研究及药物研发
【教育经历】
1. 2011.9–2016.12, 南开大学, 细胞生物学, 博士
2. 2007.9–2011.7, 山东农业大学, 生物技术, 本科
【科研与学术工作经历】
1. 2023.9–至今, 南开大学药学院, 副教授
2. 2018.10-2022.12, 南开大学, 药学院，博士后
3. 2016.12-2018.10, 南开大学, 药物化学生物学全国重点实验室，博士后
【教师简介】
主要研究方向为肺间质病及器官纤维化疾病机制研究及药物研发。以第一或通讯作者在Molecular Therapy、Science Advances等杂志发表SCI论文40余篇；发表核心论文6篇，参编著作2部；主持国家自然科学基金面上项目1项、青年项目1项，主持中国博士后科学面上基金1项，作为研究骨干参与国家级科研项目5项（包括国家科技部重大新药创制科技重大专项1项、国家自然科学基金重点项目2项、面上项目2项）；申请发明专利9项，获得国家授权发明专利5项。担任“天津市药理学会-定量药理专委会”委员。
【近期论文发表情况】
1. Xiaohe Li, Yinshan Fang, Dingyuan Jiang, Yingying Dong, Yingying Liu, Si Zhang, Jiasen Guo, Chao Qi, Chenjing Zhao, Fangxin Jiang, Yueyue Jin, Jing Geng, Cheng Yang, Hongkai Zhang, Bin Wei, Jiurong Liang, Chen Wang, Huaping Dai, Honggang Zhou*, Dianhua Jiang*, and Wen Ning*. Targeting FSTL1 for Multiple Fibrotic and Systemic Autoimmune Diseases. Molecular Therapy, 2021.
2. Xiaohe Li, § Xiaowei Liu, § Ruxia Deng, § Shaoyan Gao, § Qiuyan Jiang, Rui Liu, Hailong Li, Yang Miao, Yunqian Zhai, Shanshan Zhang, Zhenzhen Wang, Yimeng Ren, Wen Ning, Honggang Zhou*, Cheng Yang*. Betulinic acid Attenuated Bleomycin-induced Pulmonary Fibrosis by Effectively Intervening Wnt/β-catenin Signaling. Phytomedicine, 2021.
3. Xiaohe Li†, Yanhua Wang†, Jingjing Liang†, Zhun Bi†, Hao Ruan†, Yunyao Cui, Ling Ma, Yuli Wei, Bingchen Zhou, Liang Zhang, Honggang Zhou*, Cheng Yang*. Bergenin attenuates bleomycin-induced pulmonary fibrosis in mice via inhibiting TGF-β1 signaling pathway. Phytotherapy Research, 2021.
4. Xiaohe Li, Hailong Li, Shanshan Zhang, Ruotong Zhang, Jinhe Li, Yiying Wei, Cheng Yang, Fubo Zhang*, Honggang Zhou*. Protective effect of Idelalisib on carbon tetrachloride-induced liver fibrosis via microRNA-124-3P/phosphatidylinositol-3-hydr oxykinase signalling pathway. Journal of Cellular and Molecular Medicine，2021.
5. Xiaohe Li†, Yunqian Zhai†, Buri Xi†, Wei Ma†, Jianwei Zhang, Xiaoyang Ma, Yang Miao, Yongjian Zhao, Wen Ning,*, Honggang Zhou,* and Cheng Yang. Pinocembrin Ameliorates Skin Fibrosis via Inhibiting TGF‐β1 Signaling Pathway. Biomolecules，2021.
6. Shaoyan Gao§, Xiaohe Li§, Qiuyan Jiang§, Qing Liang, Fangxia Zhang, Shuangling Li, Ruiqin Zhang, Jiaoyan Luan, Jingyan Zhu, Xiaoting Gu, Ting Xiao, Hui Huang, Shanshan Chen, Wen Ning*, Guang Yang*, Cheng Yang*, Honggang Zhou*. PKM2 promotes pulmonary fibrosis by stabilizing TGF-β1 receptor I and enhancing TGF-β1 signaling. Science Advances, 2022.
7. Kun Zhang§, Jingjing Liang§, Ning Wang, Ning Li, Yurui Jiang, Xiaohe Li*, Cheng Yang*, Honggang Zhou*, Guang Yang*. Discovery of a novel Pleuromutilin derivative as anti-IPF lead compound via high-throughput assay. European Journal of Medicinal Chemistry, 2022.
8. Xiaohe Li§, Xiaoyang Ma§, Yang Miao§, Jianwei Zhang, Buri Xi, Wenqi Li, Qianyi Zhang, Li Chen, Yue Yang, Hongli Li, Luqing Wei,* Honggang Zhou,* Cheng Yang*. Duvelisib Attenuates Bleomycin-Induced Pulmonary Fibrosis via Inhibiting the PI3K/Akt/mTOR Signaling Pathway. Journal of Cellular and Molecular Medicine, 2023.
9. Shimeng Li§, Zhichao Liu§, Xiaodan Jiao§, Jinying Gu§, Zhigang Liu, Lingxin Meng, Wenqi Li, Tiantian Zhang, Jing Liu, Dan Chai, Jiaai Liu, Zhongyi Yang, Yuming Liu, Ran Jiao, Xiaohe Li*, Honggang Zhou*, Yanping Zhang*. Selpercatinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β1 signaling pathway. Biochemical Pharmacology，2024.
10. Wenqi Li, Jing Liu, Ran Jiao, Zhigang Liu, Tiantian Zhang, Dan Chai, Lingxin Meng, Zhongyi Yang, Yuming Liu, Xiaoting Gu*, Xiaohe Li*, Cheng Yang*. Baricitinib alleviates cardiac fibrosis and inflammation induced by chronic sympathetic activation. International Immunopharmacology，2024.
11. 李霄鹤，赵晨静，李莲，宁文*. 血管内皮细胞在器官纤维化发病机制中作用的研究进展. 临床内科杂志，2022.
12. 陈莉，朱婧妍，高劭妍，谷小婷，李霄鹤*，周红刚*. 尼达尼布治疗间质性肺疾病的作用机制研究进展. 中国药理学通报，2023.